癌症中铁质的表观遗传调节:确定新型抗癌疗法的表观遗传标
Jaewang Lee1,2, Jong-Lyel Roh3,4
1Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Gyeonggi-do, 13496, Republic of Korea.
Cellular oncology (Dordrecht, Netherlands)
|July 12, 2023
概括
铁,一个由铁和脂质过氧化驱动的细胞死亡途径,在癌症中受到表观遗传调节. 了解这些表观遗传机制是开发新癌症疗法的关键.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 铁亡是一种依赖于铁的细胞死亡形式.
- 氧化应激和脂质过氧化是铁亡的关键驱动因素.
- 表观遗传修饰调节基因表达和细胞表型,而不会改变DNA序列.
研究的目的:
- 审查当前对人类癌症中铁亡的表观遗传调节的理解.
- 突出表观遗传改变在与铁亡相关的癌症进展和治疗耐药性的作用.
- 确定潜在的表观遗传标,以克服癌症性.
主要方法:
- 对影响铁亡的表观遗传修饰的文献综述.
- 对表观遗传机制的分析,包括DNA甲基化,基因素修饰,RNA修饰和非编码RNA的分析.
- 检查表观遗传变化如何影响铁灭调节器和癌症的途径.
主要成果:
- 表观遗传改变调节铁灭症的敏感性和癌症的进展.
- 表观遗传变化有助于各种癌症的治疗耐药性.
- 人们越来越了解特定的表观遗传机制及其对铁灭调节者的影响.
结论:
- 铁亡的表观遗传调节是人类癌症的一个关键因素.
- 针对表观遗传修饰提供了一个有希望的策略,以增强抗癌疗法.
- 需要进一步的研究来阐明癌症特异性的表观遗传机制,并开发新的干预措施.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Epigenetic Regulation
3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.1K
Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


